Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
Preview |
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
28MB |
Item Type: | Article |
---|---|
Title: | Anti-aquaporin 4 IgG is not associated with any clinical disease characteristics in Neuromyelitis Optica Spectrum Disorder |
Creators Name: | Schmetzer, O., Lakin, E., Roediger, B., Duchow, A., Asseyer, S., Paul, F. and Siebert, N. |
Abstract: | BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a clinically defined, inflammatory central nervous system (CNS) disease of unknown cause, associated with humoral autoimmune findings such as anti-aquaporin 4 (AQP4)-IgG. Recent clinical trials showed a benefit of anti-B cell and anti-complement-antibodies in NMOSD, suggesting relevance of anti-AQP4-IgG in disease pathogenesis. OBJECTIVE: AQP4-IgG in NMOSD is clearly defined, yet up to 40% of the patients are negative for AQP4-IgG. This may indicate that AQP4-IgG is not disease-driving in NMOSD or defines a distinct patient endotype. METHODS: We established a biobank of 63 clinically well-characterized NMOSD patients with an extensive annotation of 351 symptoms, patient characteristics, laboratory results and clinical scores. We used phylogenetic clustering, heatmaps, principal component and longitudinal causal interference analyses to test for the relevance of anti-AQP4-IgG. RESULTS: Anti-AQP4-IgG was undetectable in 29 (46%) of the 63 NMOSD patients. Within anti-AQP4-IgG-positive patients, anti-AQP4-IgG titers did not correlate with clinical disease activity. Comparing anti-AQP4-IgG-positive vs. -negative patients did not delineate any clinically defined subgroup. However, anti-AQP4-IgG positive patients had a significantly (p = 0.022) higher rate of additional autoimmune diagnoses. CONCLUSION: Our results challenge the assumption that anti-AQP4-IgG alone plays a disease-driving role in NMOSD. Anti-AQP4-IgG might represent an epiphenomenon associated with NMOSD, may represent one of several immune mechanisms that collectively contribute to the pathogenesis of this disease or indeed, anti-AQP4-IgG might be the relevant factor in only a subgroup of patients. KEY MESSAGES: No clinical differences between anti-AQP4-IgG positive or negative patients / No significant change of anti-AQP4-IgG levels during disease progression, but a non- significant increase in the mean anti-AQP4-IgG titer was visible only after multiple relapses / anti-AQP4-IgG(+) patients have a significantly (p = 0.022) higher rate of additional autoimmune diagnoses. |
Keywords: | Immunology, Autoimmunity, Neuromyelitis Optica, Aquaporin, Channelopathies, Neuromyelitis Optica, AQP4, Anti-AQP4-IgG |
Source: | Frontiers in Neurology |
ISSN: | 1664-2295 |
Publisher: | Frontiers Media SA |
Volume: | 12 |
Page Range: | 635419 |
Date: | 12 March 2021 |
Official Publication: | https://doi.org/10.3389/fneur.2021.635419 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page